Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 11/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5679757 | 1.00 | AAK1 (0.41) | AAK1EGFRSLC22A12ALDH1A1MAPT | |
| SCHEMBL5678084 | 0.89 | BRD4 (0.37) | AAK1SLC22A12ALDH1A1MAPTCTSS | |
| SCHEMBL5677813 | 0.89 | BRD4 (0.38) | SLC22A12ALDH1A1MAPTCTSK | |
| SCHEMBL5677804 | 0.89 | BRD4 (0.38) | SLC22A12ALDH1A1MAPTCTSK | |
| SCHEMBL5678090 | 0.89 | BRD4 (0.37) | AAK1SLC22A12ALDH1A1MAPTCTSS | |
| SCHEMBL5679817 | 0.87 | PPARG (0.36) | EGFRSLC22A12 | |
| SCHEMBL5679657 | 0.76 | DYRK1A (0.46) | SLC22A12ALDH1A1 | |
| SCHEMBL5679666 | 0.76 | DYRK1A (0.46) | SLC22A12ALDH1A1 | |
| SCHEMBL10967 | 0.75 | PDGFRA (0.44) | SLC22A12 | |
| SCHEMBL906047 | 0.75 | HTR2C (0.51) | SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1129078-B1 | INDAZOLE DERIVATIVES WITH 5-HT2 RECEPTOR ACTIVITY | VERNALIS RES LTD (GB) | 2006-03-15 | — | — | EP | disclosed |
| US-6552062-B1 | For therapy of central nervous system disorders; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and obesity | VERNALIS RESEARCH LIMITED (GB) | 2003-04-22 | — | — | US | disclosed |
| EP-1129078-A2 | INDAZOLE DERIVATIVES WITH 5-HT2 RECEPTOR ACTIVITY | VERNALIS RESEARCH LIMITED (GB) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000012481-A2 | INDAZOLE DERIVATIVES WITH 5-HT2 RECEPTOR ACTIVITY________________ | VERNALIS RESEARCH LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |